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Background 
Mild persistent asthma is one of four severity 
level classifications used by the National Asthma 
Education and Prevention Practice (NAEPP) 
Guideline for the Diagnosis and Management of 
Asthma.1  It is classified on the basis of clinical 
symptoms before treatment.  Mild persistent 
asthma is categorized on the basis of symptoms 
occurring on greater than two days per week but 
less than once daily or greater than two nights per 
month as well as spirometry measures of forced 
expiratory volume in one second (FEV1) or peak 
expiratory flow (PEF) > 80% and PEF variability 
of < 20%.2 
Recommended long-term control treatment for 
mild persistent asthma is daily low-dose inhaled 
corticosteroids.  Guideline-suggested alternative 
treatments include daily cromolyn, leukotriene 
modifiers, nedocromil, or sustained release 
theophylline with serum levels maintained 
between five to 15 mcg/mL.  Quick relief therapy 
with a short-acting, inhaled beta-2 bronchodilator 
is recommended as needed.2 
Because of the variability in frequency and 
intensity of mild persistent asthma symptoms, 
patients may not adhere to daily use of inhaled 
corticosteroids but rather use them 
intermittently.3,4 
 
Citation 
Boushey HA, Sorkness CA, King TS, et al.  
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Methods 
In this multicenter, double-blind trial, 225 
adult patients (18 to 65 years of age) with 
physician-diagnosed asthma who met evidence-
based mild persistent asthma criteria were 
randomized to one of three treatment groups.  
Seventy-three patients received inhaled 
budesonide 200 mcg twice daily plus zafirlukast 
placebo tablets twice daily.  Seventy-six patients 
received zafirlukast 20 mg tablets twice daily plus 
a placebo inhaler (Turbuhaler) one puff twice 
daily.  The third group of 76 patients received 
placebo zafirlukast tablets twice daily and a 
placebo inhalation of one puff twice daily.   
All three treatment groups received either 
“open-label” inhaled budesonide 800 mcg twice 
daily for ten days or oral prednisone (0.5mg/kg) 
daily for five days if their asthma exacerbated. 
Both the initial treatment phase prior to 
randomization (run-in phase) and the after-study 
treatment phase consisted of a ten to 14 day 
period of therapy with oral prednisone (0.5 
mg/kg/day), 800 mcg inhaled budesonide twice 
daily, and zafirlukast 20 mg twice daily, plus as-
needed inhaled albuterol (540 to 720 mcg) to 
eliminate any causes of airway flow obstruction.   
Participants were followed for one year.  
Routine visits were conducted and study 
parameters were recorded.  FEV1 treatment 
adherence, asthma control (using a questionnaire), 
medication side effects, and symptom-related 
difficulties and days were measured, assessed, and 
discussed.  Daily diaries were kept by participants 
during certain periods of the study.  Peak flow and 
other personal observations were recorded by the 
subjects.   
 
Results 
One hundred ninety-nine patients completed 
the study.  Patients followed the prescribed 
treatment regimens greater than 90% of the time.  
This level of adherence to protocol was similar in 
all groups.   
The change in morning PEF, the primary study 
outcome, was similar in all treatment groups.  The 
morning PEF value increases were 8.3% in the 
daily budesonide group, 7.9% in the daily 
zafirlukast group, and 7.1% in the intermittent 
treatment group (P = 0.90) corresponding to an 
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approximate 7.8% increase (32 liters per minute).  
Kaplan-Meier estimates of the time to a first 
exacerbation of asthma were similar for all 
treatment groups (P=0.39).  Similarly, there was 
no difference in multiple event exacerbations per 
patient in all treatment groups (P=0.24).  
Compared with the daily zafirlukast and 
intermittent therapy groups, the daily budesonide 
group showed the greatest improvements in the 
secondary outcomes of pre-bronchodilator FEV1 
(P=0.005), asthma control score (P<0.001), and 
number of symptom-free days score (P=0.03).  
The treatment groups did not differ in the 
secondary outcome parameters of post-
bronchodilator FEV1 scores (P=0.29) or asthma 
quality of life scores (P=0.18). 
 
Author Conclusions 
The authors concluded that it is possible to 
treat chronic mild persistent asthma in adults with 
short, intermittent courses of inhaled or oral 
corticosteroids whenever asthma exacerbations 
occur.  They caution that longer and larger studies 
will be needed before this treatment approach can 
be recommended. 
 
Commentary 
As the authors suggest, this novel approach to 
treating mild persistent asthma in adults will 
require further validation before it can be accepted 
as a treatment option.  The reality of patient 
adherence to daily inhaled corticosteroid use for 
mild persistent asthma is doubtful.  Patients with 
mild persistent asthma may not experience 
exacerbations on a daily basis or their symptoms 
are so mild that they “forget” or do not use their 
prescribed treatment.  Some may be concerned 
about the safety of using long-term inhaled 
steroids or the cost of medication.  Yet, as 
demonstrated in this study, it is possible to treat 
patients with mild persistent asthma with 
intermittent inhaled or oral corticosteroids 
[Evidence level A; high-quality RCT].3 
This study was the first trial conducted by the 
Asthma Clinical Research Network (ACRN) 
which was established in 1993 by the Division of 
Lung Diseases (DLD), and the National Heart, 
Lung and Blood Institute (NHLBI).  This study by 
Boushen et al is entitled: IMProving Asthma 
Control Trial (IMPACT).3,5   
One of the questions concerning this trial 
focuses on the cost associated with the daily use 
of “controller” therapy in asthma.  Using the 
ACRN mild persistent asthma prevalence and cost 
assumptions, daily inhaled corticosteroid use for 
mild persistent asthma treatment would increase 
expenditures by over two billion dollars each year.  
Results from IMPACT may assist in answering 
this question.6  The National Asthma Education 
and Prevention Program (NAEPP) will use the 
results from IMPACT to update guidelines in 
2006.   
In IMPACT, 411 patients initially met the 
criteria for mild persistent asthma, yet on further 
screening, 64 patients were identified with higher 
severity asthma and 30 patients had milder forms 
of asthma.  As Boushey et al discuss in their trial 
publication, the lack of a difference in the 
treatment groups may reflect the low rate of 
asthma exacerbation.3  Only adults who were 
nonsmokers with a long history of asthma and a 
lower incidence of exacerbation were included.  
The low percentage of eosinophils in sputum 
(median range 0.4% to 0.6%) and the low nitric 
oxide concentration in patient exhalations (median 
range 16.4 to 16.8 parts per billion) may suggest 
that the study population had a very mild form of 
persistent asthma.7  
Does as-needed use of inhaled corticosteroids 
predispose mild persistent asthma patients to more 
severe asthma and the progressive loss of lung 
function?  This question remains unanswered.  No 
randomized clinical studies have addressed 
asthma outcomes when airway inflammation is 
not suppressed on a daily basis.7  
A recommendation for the use of as-needed 
inhaled corticosteroids for patients with mild 
persistent asthma must be considered carefully.  
This as-needed inhaled corticosteroid use must be 
supplemented with twice daily inhaled budesonide 
or daily oral prednisone for a defined period as 
done in the study.  Furthermore, as-needed, quick-
relief therapy with a beta agonist should be used 
as defined in the NAEPP Guideline.2   
As-needed corticosteroid therapy may be 
effective in carefully selected patients who 
understand the necessity for prompt treatment of 
exacerbations with quick-relief, prescribed agents.  
Assessment of the severity of asthma must be 
carefully performed so as not to underestimate 
patient needs.  Advise patients to openly discuss 
their level of asthma control and treatment needs.  
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Watch for further studies and the updated 
NAEPP guidelines in 2006. 
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input 
from experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
 
Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based 
clinical review article.  Am Fam Physician 2002;65:251-8. 
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